These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
320 related articles for article (PubMed ID: 21196359)
1. Therapeutic advances in women's cancers. Carroll AR; Coleman RL; Sood AK Front Biosci (Schol Ed); 2011 Jan; 3(1):82-97. PubMed ID: 21196359 [TBL] [Abstract][Full Text] [Related]
2. Angiogenesis as a therapeutic target in urothelial carcinoma. Pinto A; Redondo A; Zamora P; Castelo B; Espinosa E Anticancer Drugs; 2010 Nov; 21(10):890-6. PubMed ID: 20729712 [TBL] [Abstract][Full Text] [Related]
3. Antiangiogenic therapy for breast cancer. Nielsen DL; Andersson M; Andersen JL; Kamby C Breast Cancer Res; 2010; 12(5):209. PubMed ID: 21067536 [TBL] [Abstract][Full Text] [Related]
4. The role of antiangiogenesis therapy: bevacizumab and beyond. Cortés-Funes H Clin Transl Oncol; 2009 Jun; 11(6):349-55. PubMed ID: 19531449 [TBL] [Abstract][Full Text] [Related]
5. Emerging therapies targeting tumor vasculature in multiple myeloma and other hematologic and solid malignancies. Podar K; Anderson KC Curr Cancer Drug Targets; 2011 Nov; 11(9):1005-24. PubMed ID: 21933109 [TBL] [Abstract][Full Text] [Related]
6. Influence of bevacizumab, sunitinib and sorafenib as single agents or in combination on the inhibitory effects of VEGF on human dendritic cell differentiation from monocytes. Alfaro C; Suarez N; Gonzalez A; Solano S; Erro L; Dubrot J; Palazon A; Hervas-Stubbs S; Gurpide A; Lopez-Picazo JM; Grande-Pulido E; Melero I; Perez-Gracia JL Br J Cancer; 2009 Apr; 100(7):1111-9. PubMed ID: 19277038 [TBL] [Abstract][Full Text] [Related]
7. [Novelties in the treatment for advanced renal-cell cancer]. Maráz A Orv Hetil; 2011 Apr; 152(17):655-62. PubMed ID: 21464023 [TBL] [Abstract][Full Text] [Related]
8. Vascular endothelial growth factor-targeted therapy in renal cell carcinoma: current status and future directions. Rini BI Clin Cancer Res; 2007 Feb; 13(4):1098-106. PubMed ID: 17317817 [TBL] [Abstract][Full Text] [Related]
9. VEGF inhibition and metastasis: possible implications for antiangiogenic therapy. English BC; Price DK; Figg WD Cancer Biol Ther; 2009 Jul; 8(13):1214-25. PubMed ID: 19483467 [No Abstract] [Full Text] [Related]
10. [New possibilities of targeted therapy in the treatment of hepatocellular carcinoma with the help of molecular biology]. Hagymási K; Tulassay Z Orv Hetil; 2010 Oct; 151(43):1763-8. PubMed ID: 20940115 [TBL] [Abstract][Full Text] [Related]
11. [Possibilities for inhibiting tumor-induced angiogenesis: results with multi-target tyrosine kinase inhibitors]. Török S; Döme B Magy Onkol; 2012 Mar; 56(1):3-15. PubMed ID: 22403757 [TBL] [Abstract][Full Text] [Related]
16. Adverse effects of anticancer agents that target the VEGF pathway. Chen HX; Cleck JN Nat Rev Clin Oncol; 2009 Aug; 6(8):465-77. PubMed ID: 19581909 [TBL] [Abstract][Full Text] [Related]
17. How well do angiogenesis inhibitors work? Biomarkers of response prove elusive. Brower V J Natl Cancer Inst; 2009 Jun; 101(12):846-7. PubMed ID: 19509354 [No Abstract] [Full Text] [Related]
18. Sunitinib, sorafenib and mTOR inhibitors in renal cancer. Radulovic S; Bjelogrlic SK J BUON; 2007 Sep; 12 Suppl 1():S151-62. PubMed ID: 17935273 [TBL] [Abstract][Full Text] [Related]
19. Signaling inhibitors in metastatic renal cell carcinoma. Escudier B Cancer J; 2008; 14(5):325-9. PubMed ID: 18836338 [TBL] [Abstract][Full Text] [Related]
20. Angiogenesis regulated by VEGF and its receptors and its clinical application. Shibuya M Rinsho Ketsueki; 2009 May; 50(5):404-12. PubMed ID: 19483401 [No Abstract] [Full Text] [Related] [Next] [New Search]